THAR (Tharimmune, Inc.) Forward P/E Multiple
The forward P/E ratio of Tharimmune, Inc. (THAR) reflects the current market valuation, where the value of 0.00 expresses the metric level. This trend is driven by the R&D stage and the potential for formula licensing. Growth is supported by a hybrid immunotherapy model and digital assets of the Canton network. Process stability is guaranteed by a streamlined express delivery system for biocomponents, which minimizes logistical disruptions during drug development.
Summary analytical data breakdowns for Tharimmune (THAR)
- current price and projected stock value:
- business market valuation indicators:
- book capitalization information:
- issuer credit burden and liquidity indicators:
Total Debt to Capital Tharimmune, Inc.|THAR - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Tharimmune, Inc.|THAR - Company Cumulative Indebtedness|Debts to Book Capitalization Tharimmune|THAR - Company Long-Term Loans and Borrowings|Company Short-Term Debts Tharimmune|Quick Liquidity tharimmune.com
- financial results and valuation multiples details:
THAR - Final Profit|Projected Future Earnings Tharimmune, Inc.|THAR - Business Payback Period|Future Price to Earnings tharimmune.com|THAR - Price/Earnings to Growth Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tharimmune|THAR - Operating profit before deduction of amortization|Net earnings per share for the last 12 months Tharimmune|THAR - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months tharimmune.com|THAR - Earnings per share growth this year|Earnings growth forecast for next year Tharimmune, Inc.
- sales volume and revenue indicators:
Summary company analysis:Tharimmune Corp
Patents for nanobodies targeting inflammatory skin diseases create a high barrier to entry, protecting the market share of Tharimmune, Inc. (THAR) from competitors. By analyzing the company's forward P/E ratio, an investor can see the relationship between the current share price and expected earnings, which allows for an assessment of the premium paid for future growth and the determination of the fair value of capital over time.
Direct competitors
Forward P/E Multiple ONC|HALO (Halozyme Inc.) - Future Price to Earnings Multiple|Forward P/E Multiple RVMD (revmed.com)|AAPG - Projected Price to Earnings|CGON: Projected Price to Earnings|URGN - Forward P/E Multiple|Bicara Bio (BCAX) - Future Price to Earnings|Personalis Corp - Future Price to Earnings Multiple|ERAS (Erasca Inc) - Forward P/E Multiple|Projected Price to Earnings Ratio Delcath Systems, Inc. DCTH|Projected Price to Earnings YMAB (Y-mAbs Corp)|Forward P/E Multiple Aura Bio (AURA)|Forward P/E Multiple CADL (Candel Therapeutics Inc.)|ARAY - Projected Price to Earnings|SLS - Future Price to Earnings|Actuate Therapeutics - Market Cap to Future Earnings Ratio|CTOR: Forward P/E Multiple|TuHURA (HURA) - Forward P/E Multiple|TARA (Protara Therapeutics Inc) - Forward P/E Multiple|FATE: Future Price to Earnings Multiple|Forward P/E Multiple WHWK|TCRX (TScan) - Future Price to Earnings Multiple|Future Price to Earnings Champions Oncology, Inc. CSBR|XBIT - Projected Price to Earnings|CEL-SCI - Forward P/E Multiple|OSTX - Forward P/E Multiple|Radiopharm Theranostics Limited (RADX) - Future Price to Earnings|ARTV - Market Cap to Projected Earnings|Projected Price to Earnings ANL|Future Price to Earnings VERU|Forward P/E Multiple TPST|XLO: Price to Expected Earnings Ratio|Forward P/E Multiple RENB (Renovaro Inc.)|Mural Bio (MURA) - Projected Price to Earnings Ratio|Kairos Pharma Ltd - Forward P/E Multiple|Price to Expected Earnings Ratio OKUR|CytoMed Therapeutics Limited (GDTC) - Future Price to Earnings|CRIS - Market Cap to Projected Earnings|Projected Price to Earnings APLM|Price to Future Earnings Ratio ADVB (Advanced Biomed)|Projected Price to Earnings GNPX (Genprex, Inc)|CLDI: Price to Expected Earnings Ratio|Future Price to Earnings sunshinebiopharma.com SBFM|XBIO - Projected Price to Earnings|SLRX: Projected Price to Earnings|Purple Biotech - Market Cap to Future Earnings Ratio|American Oncology Network (AONC) - Future Price to Earnings|Price to Future Earnings Ratio BGNE|Projected Price to Earnings CKPT|Future Price to Earnings ELEV|Forward P/E Multiple ICAD|Forward P/E Multiple Ikena Oncology Inc. (IKNA)|Forward P/E Multiple NTBL (Notable Labs Ltd)|Market Cap to Projected Earnings Viracta Therapeutics (VIRX)|MOR: Projected Price to Earnings|NAYA (NAYA Bio) - Price to Future Earnings Ratio|AAPGV: Forward P/E Multiple
